average blood glucose concentration over approximately 3 months, and it is not affected by the fasting status or short-term changes in lifestyle. 6 The ADA and the WHO suggest HbA1c ≥48 mmol/mol (≥6.5%) as the standard cut-off point for the diagnosis of diabetes.
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HbA1c plays an important role in monitoring glycemic control in patients with diabetes. 6 The clinical guidelines described by the ADA and the National Institute for Health and Care Excellence (NICE) show that a fluctuation of 6 mmol/mol (0.5%) of HbA1c is related to a significant difference 6, 8 in the management of diabetes.
In recent years, there has been an increasing desire for the use of point-of-care testing (POCT) among both primary care clinicians and patients. 9 POCT HbA1c analyzers have obvious advantages because they are small and portable, require a tiny blood volume, and have a convenient operation and easy storage of the reagent. Approximately 75% of medical institutions in Europe have adopted POCT HbA1c analyzers. 10, 11 In China, community medical institutions serve as the healthcare providers for the majority of the population, and diabetic monitoring work is mainly completed by the community medical institutions. Therefore, POCT HbA1c analyzers are particularly desirable for use in community medical institutions in China. However, as noted in previous studies, [12] [13] [14] [15] [16] there has been notable variability in the validity of some POCT HbA1c analyzers, which has limited their clinical application.
The purpose of this study was to evaluate the performance of a new POCT HbA1c analyzer (Botangping ® A1C EZ 2.0, hereinafter referred to as A1C EZ 2.0). We compared the HbA1c results measured by the A1C EZ 2.0 with the results measured by the Tosoh G8 HPLC Analyzer (a traceable to International Federation of Clinical Chemistry (IFCC) reference method instrument) using EDTA-anticoagulated fresh venous whole-blood samples. We evaluated the accuracy, precision, linearity, diagnostic sensitivity, and diagnostic specificity. In addition, this study also compared the HbA1c levels measured by the A1C EZ 2.0 using different types of samples (capillary blood vs venous blood) and different reagent lots.
| MATERIALS AND METHODS
This study protocol was approved by the medical ethics committee of our institution.
The operator was a technologist located in the clinical laboratory.
| Evaluation of the POCT HbA1c analyzer against the comparative instrument traceable to the IFCC reference method
The POCT HbA1c analyzer A1C EZ 2.0 (BioHermes, Wuxi, China) is based on boric acid affinity chromatography. In this experiment, the reagent lot numbers were AMC15121501 (code501), AMC15121502
(code502), and AP16112803 (code652). The quality control products used were made by Canterbury Scientific Ltd. (lot No. 0105P;
Christchurch, New Zealand). The manufacture's operating procedure was strictly followed.
The comparative instrument was the Tosoh G8 HPLC Analyzer (Tosoh Corporation, Tokyo, Japan), which uses ion-exchange high-performance liquid chromatography (HPLC) for automatic HbA1c anemia, hemolytic disease, red cell abnormalities, nephropathy, and jaundice. 18 Each specimen was measured twice. If the absolute difference of the repeated measurements exceeded four times of the average absolute standard deviation, the set of data responsible for the outlier values was rejected. All specimens were tested in strict accordance with the operating procedures of the NGSP. The specimens were stored at 2-8°C, and the testing was completed within 48 hours after blood collection.
19,20
Precision of the A1C EZ 2.0 analyzer was evaluated according to CLSI EP05-A3. 21 We used quality control samples (Canterbury Scientific Ltd.) for two levels of HbA1c, including a low concentration of 36 mmol/mol (5.4%) and a high concentration of 107 mmol/mol (11.9%). Each quality control product was divided into two batches, with each batch being tested once in the morning and once in the afternoon at an interval of 2 hours. We repeatedly ran this procedure each day for 10 consecutive days. 14 Specimen retrieval, preservation, and processing were performed following the manufacturer's instructions.
We calculated the coefficients of variation (CV) and reference change values (RCV) for each of the 40 samples, which were tested twice, using EP Evaluator software (Data Innovations LLC., Burlington, VT, USA). The calculation was performed using the formulas in (1) and (2):
where CV a is analysis CV, Δ is the difference between duplicates, n is the number of duplicates, and X is the mean of the duplicates.
where CV a is analysis CV, and CV wp is individual or biological CV.
In a recent study that assessed the biological variation of HbA1c in 21
presumably healthy hospital employees, the CV wp was 0.8%.
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Linearity was assessed following the CLSI EP06-A guidelines.
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By mixing a high-concentration (124 mmol/mol, 13.5%) and a 
| Sensitivity and specificity of the POCT HbA1c analyzer for diabetes diagnosis
We assessed the sensitivity and specificity of the POCT HbA1c analyzer for diabetes diagnosis in a case-control study. The subjects, including 230 diabetic patients and 230 controls, were recruited from adults (≥18 years old) who underwent routine physical examination in the same hospital in Beijing, China. The male to female ratio was 1:1.
The sample size was calculated using the statistical software PASS 2008 (NCSS, Kaysville, UT, USA). Based on our preliminary data and literature findings, we estimated that at least 198 subjects were needed in each group, given that α was 0.05 and the one-sided test 1-β was 0.9. After considering a 15% nonresponse rate and other factors, the required sample size was 228 subjects in each group. Therefore, we had sufficient statistical power with 230 cases and 230 controls in this study.
The questionnaire information included gender, age, height, body weight, clinical diagnosis, medication use, and other laboratory testing analytes. EDTA-anticoagulated venous blood specimens were collected, and the specimens were transported and stored at 2-8°C. The testing was finished within 48 hours after blood collection.
Diabetes mellitus was defined according to the ADA diagnostic criteria for diabetes mellitus. 24 The prediabetes group was defined as 
| Statistical analysis

| RESULTS
We observed a high accuracy and precision as well as reasonable Pearson's correlation coefficient was 0.978. At 48 mmol/mol (6.5%) using the POCT HbA1c analyzer, the relative bias was 0.8% compared to the Tosoh G8 HPLC Analyzer (Figure 1 ). Using the CLSIEP5-A3 to evaluate the precision of the results, we found that at a low concentration of 36 mmol/mol (5.4%), the CVr was 3.0%, CV T was 3.7%, and the standard bias was 2 mmol/mol (0.2%). At a high concentration of 107 mmol/mol (11.9%), the CVr was 1.3%, CV T was 2.7%, and the standard bias was 3 mmol/mol (0.3%). According to the CLSI EP9-A3 of duplicate testing for precision evaluation, the analysis CV and RCV were 0.7% and 2.9%, respectively, at 40 mmol/mol (5.8%), and 0.8% We also evaluated the diagnostic sensitivity and specificity of the analyzers in this study. We collected data and samples from 842 subjects undergoing physical examination in communities from six districts in Beijing: 154 subjects from Dongcheng District, 167 subjects from Xicheng District, 165 subjects from Chaoyang District, 144 subjects from Haidian District, 135 subjects from Daxing District, and 77 subjects from Tongzhou District. There were 449 men and 393 women, and the mean age was 55.1 years old in men and 51.5 years old in women. The A1C EZ 2.0 showed a high diagnostic potential. As shown in Figure 3 0.758, and the corresponding cut-off point was 44 mmol/mol (6.14%).
When the HbA1c was at 44 mmol/mol (6.14%), the sensitivity of this method in the clinical diagnosis of diabetes was 94.7%, and the specificity was 81.1%. The sensitivity, specificity, positive predictive value, and negative predictive value of each clinical decision value are shown in Table 1 .
We further divided the 842 subjects in this study into five groups 
| DISCUSSION
In this study, we evaluated the performance of a POCT HbA1c analyzer (ie, A1C EZ 2.0) in comparison with the Tosoh G8 HPLC Analyzer traceable to the IFCC reference method, according to CLSI protocols.
Our findings indicate that the A1C EZ 2.0 has a high accuracy and precision with a wide linear range for HbA1c testing, which met or exceeded the quality requirements according to the CLSI. It also has a reasonably high discriminative value for the diagnosis of diabetes.
HbA1c has been widely used as an indicator to reflect the average concentration of blood glucose and to monitor glycemic control in the clinical management of diabetes. In clinical application, the quality of the HbA1c instrument may directly affect diabetes diagnosis and treatment in patients. 26 Previous studies have shown that the performance of some, but not all, [12] [13] [14] [15] [16] POCT HbA1c analyzers is similar to the performances of central laboratory HbA1c instruments.
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In our study, the A1C EZ 2.0 analyzer used is a new POCT instrument that adopts boronic acid affinity chromatographic technology.
In the evaluation of testing performance, the mean deviation of the A1C EZ 2.0 vs the Tosoh G8 HPLC Analyzer was 4.5%, which is in Pathologists (CAP) standard. 27 The precision of the A1C EZ 2.0 as evaluated according to EP 05-A3 and EP 09-A3 in our study was also in line with the NGSP and CAP standards at higher concentration (<3%).
For lower concentration, the total precision surpassed the precision standard, the effect from operating staff could not be omitted. In this study, the linearity of the analyzer and reagents with different lot numbers was evaluated, and the quality requirements were met.
We also found that the A1C EZ 2.0 had an excellent performance on the diagnosis of diabetes, especially at 44 mmol/mol (6.14%). The Our results indicated that the performance of the A1C EZ 2.0 analyzer met the quality requirements at the key cut-off points of clinical diabetes diagnosis.
According to the ROC curve analysis of five groups ranging from healthy subjects to diabetes patients with high HbA1c levels, the AUC had a tendency to become more and more close to 1 as the measured HbA1c results increased from low to high. At HbA1c levels >39 mmol/ mol (5.7%), the discriminative value of the A1C EZ 2.0 compared to the Tosoh G8 HPLC Analyzer was significantly higher. In addition, the κ test of the five groups of data also showed a high consistency between the two methods. These results indicated that the A1C EZ 2.0 analyzer could be suitable for routine diabetes management.
The A1C EZ 2.0 manufacturer recommends using capillary blood for testing nearby patients. For the convenience of regular comparison of the HbA1c results in the same medical institution, we compared the HbA1c levels measured by the A1C EZ 2.0 in venous blood with capillary blood. We found that the two blood collection methods had no significant differences. These results were consistent with previous findings that the HbA1c levels in capillary blood and venous blood samples are highly correlated. 30, 31 It is also noteworthy that the A1C EZ 2.0 is equipped with a smartphone application, which provides convenience for physicians to save the results and give feedback to the patients.
There were two limitations in this study. Firstly, when the precision was evaluated based on EP 05-A3, 10 days precision data were used instead of that of 20 days, mainly in the consideration of the stability of quality controls. Secondly, the cut-off value established distinguishing non-diabetics from diabetics was a little bit lower than that of large-scale epidemiological studies, the possible reason was the relative small sample number.
In conclusion, the POCT HbA1c analyzer (A1C EZ 2.0) has a high accuracy and precision with a wide range of linearity, compared to a central laboratory instrument. It met analytical quality specifications and could be suitable in the clinical management of diabetes mellitus.
